Study of SCB01A in Patient With Head and Neck Cancer
An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment
Sponsor: SynCore Biotechnology Co., Ltd.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from SynCore Biotechnology Co., Ltd.
More terminations from SynCore Biotechnology Co., Ltd.
Other Head and Neck Squamous Cell Carcinoma trials with similar outcome
This PHASE2 trial investigates Head and Neck Squamous Cell Carcinoma and is currently terminated or withdrawn. SynCore Biotechnology Co., Ltd. leads this study, which shows 11 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Jul 2023 [monthly]
Terminated PHASE2
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — May 2019 [monthly]
Terminated PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SynCore Biotechnology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .